328 related articles for article (PubMed ID: 29237796)
1. CSF neurofilament light concentration is increased in presymptomatic
Rostgaard N; Roos P; Portelius E; Blennow K; Zetterberg H; Simonsen AH; Nielsen JE
Neurology; 2018 Jan; 90(2):e157-e163. PubMed ID: 29237796
[TBL] [Abstract][Full Text] [Related]
2. Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation.
Toft A; Roos P; Jääskeläinen O; Musaeus CS; Henriksen EE; Johannsen P; Nielsen TT; Herukka SK; Hviid Simonsen A; Nielsen JE
Dement Geriatr Cogn Disord; 2020; 49(6):533-538. PubMed ID: 33626531
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
5. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.
Illán-Gala I; Alcolea D; Montal V; Dols-Icardo O; Muñoz L; de Luna N; Turón-Sans J; Cortés-Vicente E; Sánchez-Saudinós MB; Subirana A; Sala I; Blesa R; Clarimón J; Fortea J; Rojas-García R; Lleó A
Neurology; 2018 Oct; 91(17):e1619-e1628. PubMed ID: 30291183
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
7. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.
Meeter LHH; Vijverberg EG; Del Campo M; Rozemuller AJM; Donker Kaat L; de Jong FJ; van der Flier WM; Teunissen CE; van Swieten JC; Pijnenburg YAL
Neurology; 2018 Apr; 90(14):e1231-e1239. PubMed ID: 29514947
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.
Landqvist Waldö M; Frizell Santillo A; Passant U; Zetterberg H; Rosengren L; Nilsson C; Englund E
BMC Neurol; 2013 May; 13():54. PubMed ID: 23718879
[TBL] [Abstract][Full Text] [Related]
10. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
11. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
[TBL] [Abstract][Full Text] [Related]
13. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
[TBL] [Abstract][Full Text] [Related]
14. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
[TBL] [Abstract][Full Text] [Related]
15. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
16. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults.
Sprecher KE; Koscik RL; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Sager MA; Asthana S; Johnson SC; Benca RM; Bendlin BB
Neurology; 2017 Aug; 89(5):445-453. PubMed ID: 28679595
[TBL] [Abstract][Full Text] [Related]
17. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
18. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
19. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia.
van der Ende EL; Xiao M; Xu D; Poos JM; Panman JL; Jiskoot LC; Meeter LH; Dopper EG; Papma JM; Heller C; Convery R; Moore K; Bocchetta M; Neason M; Peakman G; Cash DM; Teunissen CE; Graff C; Synofzik M; Moreno F; Finger E; Sánchez-Valle R; Vandenberghe R; Laforce R; Masellis M; Tartaglia MC; Rowe JB; Butler CR; Ducharme S; Gerhard A; Danek A; Levin J; Pijnenburg YA; Otto M; Borroni B; Tagliavini F; de Mendonca A; Santana I; Galimberti D; Seelaar H; Rohrer JD; Worley PF; van Swieten JC;
J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):612-621. PubMed ID: 32273328
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.
Scherling CS; Hall T; Berisha F; Klepac K; Karydas A; Coppola G; Kramer JH; Rabinovici G; Ahlijanian M; Miller BL; Seeley W; Grinberg LT; Rosen H; Meredith J; Boxer AL
Ann Neurol; 2014 Jan; 75(1):116-26. PubMed ID: 24242746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
